Search Results - "BOZHOK, Alla"

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort by Gianni, Luca, Dr, Eiermann, Wolfgang, MD, Semiglazov, Vladimir, MD, Lluch, Ana, PhD, Tjulandin, Sergei, MD, Zambetti, Milvia, MD, Moliterni, Angela, MD, Vazquez, Federico, MD, Byakhov, Mikhail J, PhD, Lichinitser, Mikhail, MD, Climent, Miguel Angel, MD, Ciruelos, Eva, MD, Ojeda, Belen, MD, Mansutti, Mauro, MD, Bozhok, Alla, PhD, Magazzù, Domenico, PhD, Heinzmann, Dominik, PhD, Steinseifer, Jutta, PhD, Valagussa, Pinuccia, BS, Baselga, Jose, MD

“…Summary Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory…”
Get full text

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort by Gianni, Luca, Dr, Eiermann, Wolfgang, MD, Semiglazov, Vladimir, MD, Manikhas, Alexey, MD, Lluch, Ana, MD, Tjulandin, Sergey, MD, Zambetti, Milvia, MD, Vazquez, Federico, MD, Byakhow, Mikhail, MD, Lichinitser, Mikhail, MD, Climent, Miguel Angel, MD, Ciruelos, Eva, MD, Ojeda, Belén, MD, Mansutti, Mauro, MD, Bozhok, Alla, MD, Baronio, Roberta, MSci, Feyereislova, Andrea, MD, Barton, Claire, MD, Valagussa, Pinuccia, Baselga, Jose, MD

“…Summary Background The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and metastatic…”
Get full text

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer by Semiglazov, Vladimir F., Semiglazov, Vladislav V., Dashyan, Garik A., Ziltsova, Elena K., Ivanov, Vadim G., Bozhok, Alla A., Melnikova, Olga A., Paltuev, Ruslan M., Kletzel, Alexander, Berstein, Lev M.

“…BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative…”
Get full text

Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer by GIANNI, Luca, BASELGA, José, BOZHOK, Alla, MARTINEZ-AGULLO, Angel, GRECO, Marco, BYAKHOV, Mikhail, LOPEZ LOPEZ, Juan Josè, MANSUTTI, Mauro, VALAGUSSA, Pinuccia, BONADONNA, Gianni, EIERMANN, Wolfgang, GUILLEM PORTA, Vincente, SEMIGLAZOV, Vladimir, LLUCH, Ana, ZAMBETTI, Milvia, SABADELL, Dolores, RAAB, Günther, LLOMBART CUSSAC, Antonio

“…To evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary…”
Get full text

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy by GIANNI, Luca, BASELGA, José, BOZHOK, Alla, MARTINEZ-AGULLO, Angel, GRECO, Marco, BYAKHOV, Mikhail, LOPEZ, Juan Josè, MANSUTTI, Mauro, VALAGUSSA, Pinuccia, BONADONNA, Gianni, EIERMANN, Wolfgang, PORTA, Vicente Guillem, SEMIGLAZOV, Vladimir, LLUCH, Ana, ZAMBETTI, Milvia, SABADELL, Dolores, RAAB, Günther, CUSSAC, Antonio Llombart

“…Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v…”
Get full text

Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer by Gianni, Luca, Eiermann, Wolfgang, Semiglazov, Vladimir, Manikhas, Alexey, Lluch, Ana, Tjulandin, Sergei, Zambetti, Milvia, Vazquez, Federico, Byakhov, Mikhail J., Lichinitser, Mikhail, Climent, Miguel Angel, Ciruelos, Eva, Ojeda, Belen, Mansutti, Mauro, Bozhok, Alla, Magazzu, Domenico, Steinseifer, Jutta, Valagussa, Pinuccia, Baselga, Jose

“…Abstract only 503 Background: The monoclonal antibody trastuzumab (H) has been shown to improve event-free survival (EFS) and pathologic complete response…”
Get full text

Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO) by Zambetti, Milvia, Baselga, José, Eiermann, Wolfgang, Guillem, Vicente, Semiglazov, Vladimir, Lluch, Ana, Sabadell, Dolores, Bozhok, Alla, Byakhov, Mikhail J., Ojeda, Belen, Mansutti, Mauro, Mariani, Gabriella, Moliterni, Angela, Cortes-Funes, Hernan, Colozza, Marian, Pienkowski, Tadeusz, Magazzu, Domenico, Valagussa, Pinuccia, Bonadonna, Gianni, Gianni, Luca

“…Abstract only 537 Background: At the time the ECTO was designed in 1996, taxanes were only indicated for patients with metastatic breast cancer. However,…”
Get full text